Search Results

You are looking at 101 - 110 of 116 items for :

  • "novel therapy" x
  • All content x
Clear All
Full access

Jeffrey Crawford, James Armitage, Lodovico Balducci, Pamela Sue Becker, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, David P. Steensma, Mahsa Talbott, Saroj Vadhan-Raj, Peter Westervelt, Michael Westmoreland, Mary Dwyer, and Maria Ho

. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF . J Clin

Full access

Sumanta K. Pal, Matthew I. Milowsky, and Elizabeth R. Plimack

. This work was supported by NIH K12 2K12CA001727-16A1 (Dr. Pal). References 1. Pal SK Williams S Josephson DY . Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm . Mol Cancer

Full access

Patrick A. Brown, Matthew Wieduwilt, Aaron Logan, Daniel J. DeAngelo, Eunice S. Wang, Amir Fathi, Ryan D. Cassaday, Mark Litzow, Anjali Advani, Patricia Aoun, Bhavana Bhatnagar, Michael W. Boyer, Teresa Bryan, Patrick W. Burke, Peter F. Coccia, Steven E. Coutre, Nitin Jain, Suzanne Kirby, Arthur Liu, Stephanie Massaro, Ryan J. Mattison, Olalekan Oluwole, Nikolaos Papadantonakis, Jae Park, Jeffrey E. Rubnitz, Geoffrey L. Uy, Kristina M. Gregory, Ndiya Ogba, and Bijal Shah

and therefore future studies are needed to determine the utility of TKIs and novel therapies in this setting. References 1. Geyer MB , Hsu M , Devlin SM , . Overall survival among older US adults with ALL remains low despite modest

Full access

R. Michael Tuttle, Douglas W. Ball, David Byrd, Gilbert H. Daniels, Raza A. Dilawari, Gerard M. Doherty, Quan-Yang Duh, Hormoz Ehya, William B. Farrar, Robert I. Haddad, Fouad Kandeel, Richard T. Kloos, Peter Kopp, Dominick M. Lamonica, Thom R. Loree, William M. Lydiatt, Judith McCaffrey, John A. Olson Jr., Lee Parks, John A. Ridge, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas N. Wang, and Lori J. Wirth

). Several recent published reviews have examined novel therapies and the therapeutic approach to the management of aggressive MTC. 82 – 84 Of interest, calcitonin levels decreased dramatically after vandetanib therapy, which did not correlate directly with

Full access

perceptions of the benefits and risks of currently available therapies and how they value the different efficacy and toxicity profiles of novel therapies. This study quantified CG preferences for attributes associated with chemotherapy and immunotherapy, alone

Full access

third-line setting. Conclusion: Continued education is needed about the role of mutational testing in GIST to ensure optimal treatment, especially among U.S. community oncology practitioners. The data also highlight the need for novel therapies that

Full access

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, and Marshall M. Urist

rapidly changing with the recent development of novel agents. Novel Therapies: Ipilimumab, a monoclonal antibody directed to the immune checkpoint receptor termed cytotoxic T lymphocyte antigen-4 (CTLA-4), received FDA approval for treatment of

Full access

Crystal S. Denlinger, Tara Sanft, K. Scott Baker, Shrujal Baxi, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Allison King, Divya Koura, Elizabeth Kvale, Robin M. Lally, Terry S. Langbaum, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Javid J. Moslehi, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, M. Alma Rodriguez, Kathryn J. Ruddy, Paula Silverman, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Deborah A. Freedman-Cass, and Nicole R. McMillian

Micronized progestin may be preferred over medroxyprogesterone acetate (MPA) due to lower rates of VTE and breast cancer risk. Other hormonal options for treating hot flashes include novel therapies that combine a selective estrogen receptor modulator (SERM

Full access

Jason Gotlib, Aaron T. Gerds, Prithviraj Bose, Mariana C. Castells, Michael W. Deininger, Ivana Gojo, Krishna Gundabolu, Gabriela Hobbs, Catriona Jamieson, Brandon McMahon, Sanjay R. Mohan, Vivian Oehler, Stephen Oh, Eric Padron, Philip Pancari, Nikolaos Papadantonakis, Animesh Pardanani, Nikolai Podoltsev, Raajit Rampal, Erik Ranheim, Lindsay Rein, David S. Snyder, Brady L. Stein, Moshe Talpaz, Swapna Thota, Martha Wadleigh, Katherine Walsh, Mary Anne Bergman, and Hema Sundar

patients with advanced SM who are being treated with novel therapies (See “Response Criteria,” page 1531). 2 , 72 Imaging studies (CT/MRI or ultrasound of the abdomen/pelvis) are useful to document organomegaly, lymphadenopathy, and ascites in patients

Full access

Richard L. Theriault, J. Sybil Biermann, Elizabeth Brown, Adam Brufsky, Laurence Demers, Ravinder K. Grewal, Theresa Guise, Rebecca Jackson, Kevin McEnery, Donald Podoloff, Peter Ravdin, Charles L. Shapiro, Matthew Smith, and Catherine H. Van Poznak

on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial . J Clin Oncol 2003 ; 21 : 679 – 689 . 10.1200/JCO.2003.04.176 12586806 87. Nelson JB . Endothelin inhibition: novel therapy